Skip to Main Content

The Centers for Medicare and Medicaid services proposed a new set of policies that appear to expand the use of a procedure that allows doctors to replace the aortic heart valve without performing open-heart surgery.

The procedure, called transcatheter aortic valve replacement (TAVR), was first introduced as an alternative to surgical aortic valve replacement (SAVR) for the sickest patients, but its use has gradually expanded to more and more patients as clinical trials showed that the catheter-based approach was as good or, in some ways, better. The two leading makers of TAVR are Edwards Lifesciences, the market leader, and Medtronic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.